What is Macro Trials?
Macro Trials partners with sponsors and Contract Research Organizations (CROs) to establish high-performing clinical trial sites. The company specializes in ophthalmology, dermatology, and pulmonology, offering a turnkey model designed for rapid site activation, stringent protocol adherence, and reliable patient enrollment across diverse U.S. communities. By integrating experienced clinicians with a centralized operational framework, Macro Trials ensures the delivery of high-quality data and efficient trial execution, thereby improving patient access to novel therapies and reducing the administrative load on investigators.
How much funding has Macro Trials raised?
Macro Trials has raised a total of $6M across 1 funding round:
Angel/Seed
$6M
Angel/Seed (2023): $6M with participation from villageglobal.com, MBX Capital, INITIATE Ventures, Healthy VC, and Inflict Health
Key Investors in Macro Trials
villageglobal.com
Village Global VC is an early-stage venture capital firm that supports startups with funding, mentorship, and access to a network of successful entrepreneurs and investors. They invest between $500K and $3M in pre-seed and seed rounds globally, focusing on resourceful founders across various sectors.
MBX Capital
MBX Capital is a boutique venture capital firm that partners with and creates healthcare and biotechnology companies that are disrupting conventions in service to public health. MBX focuses primarily on early-stage companies that are inventing in overlooked domains of knowledge or which are harnessing edge effects to instigate quantum leaps in their fields.
INITIATE Ventures
Undisclosed investor participating in the funding round.
What's next for Macro Trials?
The recent major strategic investment signals a phase of accelerated growth and market expansion for Macro Trials. This capital infusion is expected to bolster the company's operational capabilities, potentially enabling broader geographic reach and the development of new service offerings. The focus on strategic partnerships suggests an intent to deepen relationships within the clinical research ecosystem, further solidifying its position as a key enabler of therapeutic advancements.
See full Macro Trials company page
